Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States.

Roland KB, Soman A, Benard VB, Saraiya M.

Am J Obstet Gynecol. 2011 Nov;205(5):447.e1-8. doi: 10.1016/j.ajog.2011.06.001. Epub 2011 Jun 12.

PMID:
21840492
2.

Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?

Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V.

Arch Intern Med. 2010 Jun 14;170(11):977-85. doi: 10.1001/archinternmed.2010.134.

PMID:
20548011
3.

Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).

Saraiya M, Irwin KL, Carlin L, Chen X, Jain N, Benard V, Montano DE.

Cancer. 2007 Sep 1;110(5):1024-32.

4.

Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers.

Lee JW, Berkowitz Z, Saraiya M.

Obstet Gynecol. 2011 Jul;118(1):4-13. doi: 10.1097/AOG.0b013e3182210034.

PMID:
21691157
5.

Cervical cancer screening, abnormal cytology management, and counseling practices in the United States.

Irwin K, Montaño D, Kasprzyk D, Carlin L, Freeman C, Barnes R, Jain N, Christian J, Wolters C.

Obstet Gynecol. 2006 Aug;108(2):397-409.

PMID:
16880312
6.

Human papillomavirus vaccine practices in the USA: do primary care providers use sexual history and cervical cancer screening results to make HPV vaccine recommendations?

Kepka D, Berkowitz Z, Yabroff KR, Roland K, Saraiya M.

Sex Transm Infect. 2012 Oct;88(6):433-5. Epub 2012 Apr 21.

PMID:
22522751
7.
8.

Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.

Cooper CP, Saraiya M, McLean TA, Hannan J, Liesmann JM, Rose SW, Lawson HW.

J Womens Health (Larchmt). 2005 Oct;14(8):670-8.

PMID:
16232098
9.

Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007.

Yabroff KR, Saraiya M, Meissner HI, Haggstrom DA, Wideroff L, Yuan G, Berkowitz Z, Davis WW, Benard VB, Coughlin SS.

Ann Intern Med. 2009 Nov 3;151(9):602-11. doi: 10.7326/0003-4819-151-9-200911030-00005.

PMID:
19884621
10.

Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists.

Perkins RB, Anderson BL, Gorin SS, Schulkin JA.

Am J Prev Med. 2013 Aug;45(2):175-81. doi: 10.1016/j.amepre.2013.03.019.

PMID:
23867024
11.

Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.

Moyer VA; U.S. Preventive Services Task Force.

Ann Intern Med. 2012 Jun 19;156(12):880-91, W312. doi: 10.7326/0003-4819-156-12-201206190-00424. Erratum in: Ann Intern Med. 2013 Jun 4;158(11):852. Ebell, Mark [added].

PMID:
22711081
13.

Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J.

N Engl J Med. 2007 Oct 18;357(16):1589-97. Erratum in: N Engl J Med. 2008 Oct 9;359(15):1637. Johansson, Bo [added].

14.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
15.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
16.

Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States.

Baseman JG, Kulasingam SL, Harris TG, Hughes JP, Kiviat NB, Mao C, Koutsky LA.

Am J Obstet Gynecol. 2008 Jul;199(1):26.e1-8. doi: 10.1016/j.ajog.2007.11.051. Epub 2008 Mar 7.

PMID:
18313636
17.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
18.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

19.

Physician recommendation for papanicolaou testing among U.S. women, 2000.

Coughlin SS, Breslau ES, Thompson T, Benard VB.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1143-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk